SYNGENE Q2 FY27 Earnings Call: Bayview Biologics Signs First Manufacturing Deal, Mid-20s Margin Guidance Held

SYNGENE held its Q2 FY27 earnings call on October 27, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Return to Profitability, But YoY Declines Persist

• Revenue of Rs.833 crore — up 13% QoQ vs Q1 FY 2026-2027 but down 9% YoY, primarily reflecting the absence of Zoetis revenue; mix was 65% discovery services / 35% CDMO.
• Operating EBITDA of Rs.147 crore — margin improved 6 percentage points sequentially to 18%, versus 22% in Q2 FY 2025-2026; the YoY decline was attributed to lower Librela revenues and a Rs.61 crore foreign exchange hedge loss booked in the quarter. Adjusted for the hedge loss, margin would be in the mid-20s.
• PAT before exceptional items of Rs.38 crore — reported PAT of Rs.32 crore (after a Rs.6 crore net-of-tax exceptional charge for employee termination benefits) versus a reported loss of Rs.9 crore in Q1 FY 2026-2027, a return to profitability.
• H1 FY 2026-2027 capital investment of ~Rs.200 crore — directed toward strategic capability development, Bayview enhancements, automation and infrastructure; net cash position of Rs.1,392 crore at end of Q2 FY 2026-2027.
• Management labeled the sequential improvement "green shoots" — explicitly cautioning that one quarter of improvement does not constitute a sustained recovery.

Bayview Milestone, Zoetis Tail, Biologics Differentiation

• First manufacturing agreement signed for the Bayview Biologics facility (US) in Q2 FY 2026-2027 with a large pharmaceutical customer — described as validation of the India-US integrated biologics strategy; process development commences in India during FY 2026-2027, with drug substance manufacturing at Bayview scheduled to begin in FY 2027-2028 and to include commercial supplies.
• Commercial supplies contingent on regulatory approval — Syngene becomes the commercial manufacturing partner only once regulators approve the product (currently not commercially approved); Rs.66 crore of pre-op expenses were capitalized in H1 FY 2026-2027, with capitalization continuing until first regulatory approvals, which management expects, best case, in H2 CY2028.
• Bayview not yet at full readiness — management said identified gaps must be fixed before full utilization and offered no quantified utilization target or timeline for peak drug-substance utilization.
• Zoetis/Librela gap — zero Zoetis supplies in Q2 FY 2026-2027 versus a significant contribution in Q2 FY 2025-2026; Librela was high-margin and its absence lowered gross margin. An obligation to supply Zoetis during FY 2026-2027 is back-end loaded into Q4 FY 2026-2027, after which Biocon Park capacity frees up for new customers.
• Biocon Park (USFDA-approved) to be occupied in H2 FY 2026-2027 — manufacturing Zoetis batches with delivery in Q4 FY 2026-2027; the site cannot manufacture for any other customer until FY 2027-2028.
• 50 KL of ready biologics capacity — analyst Sajal Kapoor flagged this as a differentiator no other Indian bio-CDMO can claim; Kiran Mazumdar-Shaw affirmed, noting most Indian peers have only microbial, not mammalian, fermentation. Additional clinical supply agreement secured for Bangalore biologics Unit 3, with multiple customers signed for clinical, development and filing batches.

FTE-to-FFS Shift Amid Structural Headwinds

• Discovery has degrown YoY and vs Q1 FY 2026-2027 — attributed to client attritions at the beginning of H1 FY 2026-2027 (flagged at the Q1 FY 2026-2027 call) and pricing pressure from large CROs in China and emerging CROs in India; Syngene is not competing on price-per-FTE.
• Structural industry headwind — management noted about one-third of total drugs under trial across different stages currently come from China under licensed models, changing the need for discovery services, a dynamic it said will impact all CROs.
• Model shift from FTE to fee-for-service (FFS) — Kiran Mazumdar-Shaw said the FTE model is commoditized with competitors undercutting any quote; illustratively, FFS work can earn $100,000 per scientist versus much lower FTE rates. She said the shift "should be very positive" for productivity and profitability, but it is "very early days."
• Discovery repositioned, not discontinued — Siddharth Mittal clarified no existing discovery business is being discontinued; discovery biology and discovery chemistry, previously two separate OUs, will be integrated into a single offering, and discovery remains "a very core part" of the company.
• Turnaround not overnight — key monitorables are new client additions, new projects onboarded and molecules progressing from discovery to development; encouraging client discussions have yet to convert into revenue.
• Indian CRO cost position — as of Q2 FY 2026-2027, Siddharth Mittal noted Indian CROs are 30-40% cheaper than Chinese CROs on FTE charge-out rates and roughly half of Europe/US CRO rates; customers increasingly value time to IND filing and total molecule budget over per-FTE rates.

Hedge Losses to Persist; Mid-20s Guidance Held

• FY27 EBITDA margin guidance maintained at mid-20s — explicitly excluding forex losses; management noted it has "done better" in H1 FY 2026-2027, with additional cost-optimization benefits expected in H2 FY 2026-2027. Analyst Shyam Srinivasan (Goldman Sachs) flagged that including FX losses, the mid-20s level may not be achieved in FY 2026-2027.
• Hedge losses to continue in H2 FY 2026-2027 — forward contracts are in place on one large dedicated customer contract running till FY28; management expects a similar level of hedge losses in Q3 and Q4 FY 2026-2027.
• Hedge policy changed — Syngene has moved toward options rather than forward contracts; once current hedges expire in FY 2027-2028, management stated the sustainable margin level is already in the mid-20s.
• SG&A at normalized levels — CEO Siddharth Mittal said the company will "endeavor" to sustain expenses at Q2 FY 2026-2027 levels, with cost-optimization initiatives delivering additional benefits in H2 FY 2026-2027; manpower cost optimization is complete, while other opex initiatives remain underway.
• Restructuring costs disclosed — a Rs.6 crore exceptional charge (net of tax) for employee termination benefits in Q2 FY 2026-2027; Kiran Mazumdar-Shaw said the organization had become "very inefficient" with extra costs from people who "did not have any roles or work cut out for them," with results of the reorganization visible over the next two quarters (Q3–Q4 FY 2026-2027).
• CFO transition — CFO Deepak Jain to leave for personal reasons, continuing in role at least until the close of Q3 FY 2026-2027 financial results to support a smooth transition.

Integrated CRDMO Pitch, Geopolitics and AI-Led Differentiation

• FY 2026-2027 framed as a year of transition — three priorities: re-energizing the commercial engine, establishing CDMO as the principal growth driver, and transforming discovery into a differentiated, technology-enabled, higher-value business; Q2 FY 2026-2027 cited as early evidence of traction.
• "China plus one" tailwind — management said current geopolitics favors Syngene; Siddharth Mittal said the BIOSECURE Act "really adds a lot of advantage," and Kiran Mazumdar-Shaw added that Syngene is seeing growing demand.
• Dual-site strategy — US-for-US and ex-US-for-rest-of-world manufacturing with a single tech transfer effort; Siddharth Mittal noted even Samsung lacks a US facility, and pricing is very competitive versus Western and Far East CMOs.
• Biologics demand "huge" — Kiran Mazumdar-Shaw said Korean players are currently capturing this opportunity and Syngene "would like to be the Indian CRDMO of choice"; in large-molecule CMO she said there is hardly any credible Indian player besides Syngene, while in small molecule the focus is on new modalities — peptides and oligonucleotides.
• Capability proof points — delivered complex GMP-level oligonucleotide manufacturing for a customer and completed a technically complex siRNA program for a leading global pharmaceutical company; in ADC conjugation, Syngene is the only company fully integrated from biologic to linker to payload and conjugation at commercial scale.
• AI/automation investments — deployed ChemVoyager (AI-enabled synthesis planning), automated analytical systems and end-to-end sample tracking; commissioned a new clinical translational science lab in Bangalore (capex undisclosed, described as "not a very large investment"). Management committed to investing in infrastructure upgrades and AI/automation/digitization in the coming quarters, with scale still being evaluated.

Guidance Unchanged, But Management Urges Patience

• No significant change to FY 2026-2027 revenue and EBITDA margin guidance at this stage — though management said "let's wait for another quarter," noting cost optimization over Q1–Q2 FY 2026-2027 has started yielding benefits.
• H2 FY 2026-2027 priorities — converting the commercial pipeline into business wins, consistent delivery on quality and timelines, improving capacity utilization, and embedding cost discipline.
• Reorganization largely complete — Kiran Mazumdar-Shaw said only some additional capability onboarding remains, aligning with leaning away from low-margin/no-margin commoditized services toward a differentiated model, aiming to regain position as a leading-edge CRO/CRDMO.
• Discovery capacity headroom — with existing labs and following recent client attrition, management stated Syngene has enough capacity and bench strength to add more customers.
• Management cautioned the discovery-to-FFS transition and AI/automation upgrades "will take time," and that success should be measured by sustained revenue growth, stronger profitability and improved returns on capital — not one quarter of sequential improvement.